{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:24:24Z","timestamp":1777731864287,"version":"3.51.4"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:p>The purpose of the study was to assess the pharmacokinetics of liposome\u2010encapsulated (DPPC\u2010C) hydromorphone administered intravenously (IV) or subcutaneously (SC) to dogs. A total of eight healthy Beagles aged 12.13\u2003\u00b1\u20031.2\u2003months and weighing 11.72\u2003\u00b1\u20031.10\u2003kg were used. Dogs randomly received liposome encapsulated hydromorphone, 0.5\u2003mg\/kg IV (<jats:italic>n<\/jats:italic>\u2003=\u20036), 1.0\u2003mg\/kg (<jats:italic>n<\/jats:italic>\u2003=\u20036), 2.0\u2003mg\/kg (<jats:italic>n<\/jats:italic>\u2003=\u20036), or 3.0\u2003mg\/kg (<jats:italic>n<\/jats:italic>\u2003=\u20037) SC with a 14\u201328\u2003day washout between trials. Blood was sampled at serial intervals after drug administration. Serum hydromorphone concentrations were measured using liquid chromatography with mass spectrometry. Serum concentrations of hydromorphone decreased rapidly after IV administration of the DPPC\u2010C formulation (half\u2010life\u2003=\u20030.52\u2003h, volume of distribution\u2003=\u200312.47\u2003L\/kg, serum clearance\u2003=\u2003128.97\u2003mL\/min\/kg). The half\u2010life of hydromorphone after SC administration of DPPC\u2010C formulation at 1.0, 2.0, and 3.0\u2003mg\/kg was 5.22, 31.48, and 24.05\u2003h, respectively. The maximum serum concentration normalized for dose (C<jats:sub>MAX<\/jats:sub>\/D) ranged between 19.41\u201324.96\u2003ng\/mL occurring at 0.18\u20130.27\u2003h. Serum hydromorphone concentrations fluctuated around 4.0\u2003ng\/mL from 6\u201372\u2003h after 2.0\u2003mg\/kg and mean concentrations remained above 4\u2003ng\/mL for 96\u2003h after 3.0\u2003mg\/kg DPPC\u2010C hydromorphone. Liposome\u2010encapsulated hydromorphone (DPPC\u2010C) administered SC to healthy dogs provided a sustained duration of serum hydromorphone concentrations.<\/jats:p>","DOI":"10.1111\/j.1365-2885.2008.00974.x","type":"journal-article","created":{"date-parts":[[2008,6,17]],"date-time":"2008-06-17T17:03:32Z","timestamp":1213722212000},"page":"415-422","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacokinetics of a controlled\u2010release liposome\u2010encapsulated hydromorphone administered to healthy dogs"],"prefix":"10.1111","volume":"31","author":[{"given":"L. J.","family":"SMITH","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"KuKANICH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. K.","family":"HOGAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"BROWN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. D.","family":"HEATH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"KRUGNER\u2010HIGBY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,9,30]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"518","article-title":"Evaluation of liposome encapsulated (LE) oxymorphone hydrochloride in mice after splenectomy mice","volume":"54","author":"Clark M.D.","year":"2004","journal-title":"Comparative Medicine"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)03336-8"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(96)03213-7"},{"key":"e_1_2_6_5_1","first-page":"877","article-title":"Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids","volume":"38","author":"Hennies H.H.","year":"1988","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020134521778"},{"key":"e_1_2_6_7_1","first-page":"270","article-title":"Liposome\u2010encapsulated oxymorphone hydrochloride provides prolonged relief of post\u2010surgical visceral pain in rats","volume":"53","author":"Krugner\u2010Higby L.","year":"2003","journal-title":"Comparative Medicine"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2995.2007.00379.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)00018-3"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-197505000-00021"},{"key":"e_1_2_6_11_1","first-page":"109","article-title":"Methadone\u2010induced respiratory depression in the dog: comparison of steady\u2010state and rebreathing techniques and correlation with serum drug concentration","volume":"207","author":"Schlitt S.C.","year":"1978","journal-title":"Journal of Pharmacoogy and Experimental Therapeutics"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(82)90455-6"},{"key":"e_1_2_6_13_1","first-page":"280","article-title":"A single dose of liposome\u2010encapsulated oxymorphone or morphine provides long\u2010term analgesia in an animal model of neuropathic pain","volume":"53","author":"Smith L.J.","year":"2003","journal-title":"Comparative Medicine"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2004.00582.x"},{"key":"e_1_2_6_15_1","first-page":"487","article-title":"A single dose of liposome\u2010encapsulated hydromorphone provides extended relief of hyperalgesia in a rodent model of neuropathic pain","volume":"56","author":"Smith L.J.","year":"2006","journal-title":"Comparative Medicine"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2004.00600.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.5.1126"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2885.2008.00974.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2885.2008.00974.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T17:58:34Z","timestamp":1697047114000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2885.2008.00974.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,30]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1111\/j.1365-2885.2008.00974.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2885.2008.00974.x","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,30]]}}}